Myriad Genetics (MYGN) Inventory (2011 - 2026)

Myriad Genetics (MYGN) has reported Inventory for 16 consecutive years, with $27.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Inventory fell 1.41% year-over-year to $27.9 million; the TTM figure through Mar 2026 stood at $27.9 million (down 1.41% YoY), while the FY2025 annual figure was $30.6 million, up 11.27% from the prior year.
• Inventory declined to $27.9 million in Q1 2026 per MYGN's latest filing, from $30.6 million in the prior quarter.
• Across five years, Inventory topped out at $31.6 million in Q3 2025 and bottomed at $15.4 million in Q2 2022.
• Historically, Inventory has averaged $24.3 million across 5 years, with a median of $25.1 million in 2023.
• Annual changes were most pronounced in 2022 — Inventory tumbled 36.59% — and 2023, when it soared 46.1%.
• Myriad Genetics' Inventory stood at $20.1 million in 2022, then climbed by 9.45% to $22.0 million in 2023, then climbed by 25.0% to $27.5 million in 2024, then climbed by 11.27% to $30.6 million in 2025, then fell by 8.82% to $27.9 million in 2026.
• Business Quant data shows MYGN's Inventory at $27.9 million in Q1 2026, $30.6 million in Q4 2025, and $31.6 million in Q3 2025.